Mircera®

BIOLOGICAL2 trials

Sponsors

Biocad, Akebia Therapeutics

Conditions

Anemia Associated With Chronic Kidney Disease (CKD)Reticulocyte Count

Phase 1

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

CompletedNCT02731469

BiocadReticulocyte Count

Start: 2016-06-15End: 2017-03-31Updated: 2019-07-01

Phase 3

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

CompletedNCT04707768

Akebia TherapeuticsAnemia Associated With Chronic Kidney Disease (CKD)

Start: 2021-06-18End: 2023-01-30Updated: 2025-01-15

Related Papers

Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.

2024-11-072 citations